Recordati S.p.A. - Recordati obtains license for a new antiallergy drug in Spain

Press Releases

Recordati obtains license for a new antiallergy drug in Spain

Milan, 4 September 2003

Recordati announced that it has signed a license agreement with the Spanish pharmaceutical company Grupo Uriach for the marketing and sale in Spain of rupatadine, an antihistamine indicated for the treatment of allergies.

Rupatadine, researched and developed by Uriach and recently approved in Spain, is a latest generation systemic antihistamine and does not cause sleepiness, an undesired side effect of previous generation drugs. The market for this class of drugs in Spain in 2002 was over € 60 million. Rupatadine will be launched by Recordati España in the fourth quarter 2003.

"This agreement consolidates our excellent collaboration with Uriach, our licensee of lercanidipine in Spain for the past five years, and allows us to strengthen our pipeline with a competitive product in an interesting market" declared Vittorio Bonazzi, Vice-President and General Manager Pharmaceuticals of Recordati.

"This is another step that fits with our strategy of growing through partnerships and make the best out of our pipeline. We believe in alliances that go beyond occasional transactions, and our relationship with Recordati is a good example of this" said Dr. Juan Uriach, President of Grupo Uriach."

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Ireland, Portugal, Spain, Switzerland and the United States.

		Home Site Map Alert Service Versione Italiana
About us Pharmaceutical operations Rare diseases Investors Corporate Governance Publications Join Us Contacts
Home Investors Press Releases 2003 Print Page Bookmark Page
Shareholder information Recordati at a glance Key Financial Data Recordati Share Press Releases 2008 2007 2006 2005 2004 2003 2002 2001 2000 Company Presentations Annual and Interim Reports Calendar Analyst Coverage Contacts	Press Releases Recordati obtains license for a new antiallergy drug in Spain Milan, 4 September 2003 Recordati announced that it has signed a license agreement with the Spanish pharmaceutical company Grupo Uriach for the marketing and sale in Spain of rupatadine, an antihistamine indicated for the treatment of allergies. Rupatadine, researched and developed by Uriach and recently approved in Spain, is a latest generation systemic antihistamine and does not cause sleepiness, an undesired side effect of previous generation drugs. The market for this class of drugs in Spain in 2002 was over € 60 million. Rupatadine will be launched by Recordati España in the fourth quarter 2003. "This agreement consolidates our excellent collaboration with Uriach, our licensee of lercanidipine in Spain for the past five years, and allows us to strengthen our pipeline with a competitive product in an interesting market" declared Vittorio Bonazzi, Vice-President and General Manager Pharmaceuticals of Recordati. "This is another step that fits with our strategy of growing through partnerships and make the best out of our pipeline. We believe in alliances that go beyond occasional transactions, and our relationship with Recordati is a good example of this" said Dr. Juan Uriach, President of Grupo Uriach." Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Ireland, Portugal, Spain, Switzerland and the United States.